COMMUNIQUÉS West-GlobeNewswire

RadioMedix Announces Receiving FDA Approval of its Generic Ga-68 PSMA-11 Radiodiagnostic for Prostate Cancer
10/06/2026
Approval follows FDA inspection of RadioMedix’s manufacturing site with no Form 483 observations, underscoring the Company’s radiopharmaceutical manufacturing and quality capabilities HOUSTON, June 10, 2026 (GLOBE [...]
Urteste S.A. enrolls the first patient in the Panuri test clinical study
10/06/2026
Urteste S.A. enrolls the first patient in the Panuri test clinical study Gdańsk, Poland – 10 June 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer [...]
Cosmos Health CEO Issues Letter to Shareholders: Building an Innovative AI-Driven Global Healthcare Platform — Record Growth with U.S. Expansion Underway
10/06/2026
Key Highlights Record revenue, continued momentum: all-time high $65.3M in FY2025; strongest-ever Q1 2026, carrying into Q2. Record operational momentum: CosmoFarm wholesale distribution and GMP-certified Cana contract [...]
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
10/06/2026
Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL
10/06/2026
New Clinical Data, Patient Reported Outcomes, Real-World Utilization, and Comparative-Effectiveness Models to be Featured in Four Oral and One Poster Presentation PRINCETON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Kyowa [...]
Ligand Announces 2026 Investor Day in New York City
10/06/2026
JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 10:30 a.m. Eastern [...]
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
10/06/2026
Study using Nexalin’s proprietary DIFS ™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results further validate [...]
genXtraits, Mendel Biotechnology and AgGene Announce Collaboration to Develop Stress-Resilient Canola Traits
10/06/2026
SAN FRANCISCO, June 10, 2026 (GLOBE NEWSWIRE) -- San Francisco Bay Area based biotechnology firms, genXtraits Inc. (genXtraits) and Mendel Biotechnology, Inc. (Mendel), have announced a joint collaboration with AgGene [...]
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
10/06/2026
CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA multi-dose regimen [...]
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
10/06/2026
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and [...]
DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
10/06/2026
New solution integrates speech recognition, clinical AI findings, measurements, AI-generated impressions and quality assurance SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI [...]
Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment
10/06/2026
Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD community NDS is based on Italfarmaco’s Phase 3 EPIDYS trial data [...]
Tilray Medical Germany Launches ARX™, a New Premium Medical Cannabis Brand Cultivated in Germany
10/06/2026
New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany NEUMÜNSTER, Germany, June 10, 2026 (GLOBE NEWSWIRE) -- [...]
Reacta Healthcare Receives Extended MHRA Pharmaceutical Manufacturer’s Licence and GMP Certificate
10/06/2026
DEESIDE, United Kingdom, June 10, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces [...]
Italfarmaco annonce l’acceptation du dépôt et l’examen prioritaire par Santé Canada pour la présentation de drogue nouvelle du givinostat dans le traitement de la dystrophie musculaire de Duchenne
10/06/2026
L’examen prioritaire de Santé Canada vise un délai accéléré de 180 jours pour l’examen du givinostat, reflétant l’engagement d’Italfarmaco envers la communauté canadienne touchée par la dystrophie musculaire de Duchenne [...]
IBA annonce une collaboration de recherche visant à renforcer les preuves sur la valeur de la protonthérapie
10/06/2026
Louvain-la-Neuve, Belgique, le 10 juin 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de protonthérapie pour [...]
Cytospire Therapeutics Appoints Samit Hirawat, M.D., as Non-Executive Director
10/06/2026
Dr Hirawat i s the former CMO and Head of Global Drug Development at Bristol Myers Squibb and former EVP and Head of Oncology Development at Novartis Augments Cytospire’s clinical development experience as Cytospire [...]
IBA Announces Research Collaboration to Strengthen Evidence on the Value of Proton Therapy
10/06/2026
Louvain-la-Neuve, Belgium, June 10, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of proton therapy solutions for the treatment of cancer [...]
Vara receives CE mark for tomosynthesis AI - extending Europe’s leading screening-grade AI portfolio to 3D
10/06/2026
BERLIN, June 10, 2026 (GLOBE NEWSWIRE) -- Vara, the AI company powering more than half of Germany’s organized breast cancer screening program, today received CE class 2b marking under EU MDR for its tomosynthesis (3D [...]

Pages